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Abstract
Background: Tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) are the
three components of the once-daily, single tablet regimen (Atripla) for treatment of HIV-1 infection.
Previous cell culture studies have demonstrated that the double combination of tenofovir (TFV), the
parent drug of TDF, and FTC were additive to synergistic in their anti-HIV activity, which correlated with
increased levels of intracellular phosphorylation of both compounds.
Results:  In this study, we demonstrated the combinations of TFV+FTC, TFV+EFV, FTC+EFV, and
TFV+FTC+EFV synergistically inhibit HIV replication in cell culture and synergistically inhibit HIV-1 reverse
transcriptase (RT) catalyzed DNA synthesis in biochemical assays. Several different methods were applied
to define synergy including median-effect analysis, MacSynergy®II and quantitative isobologram analysis.
We demonstrated that the enhanced formation of dead-end complexes (DEC) by HIV-1 RT and TFV-
terminated DNA in the presence of FTC-triphosphate (TP) could contribute to the synergy observed for
the combination of TFV+FTC, possibly through reduced terminal NRTI excision. Furthermore, we
showed that EFV facilitated efficient formation of stable, DEC-like complexes by TFV- or FTC-
monophosphate (MP)-terminated DNA and this can contribute to the synergistic inhibition of HIV-1 RT
by TFV-diphosphate (DP)+EFV and FTC-TP+EFV combinations.
Conclusion: This study demonstrated a clear correlation between the synergistic antiviral activities of
TFV+FTC, TFV+EFV, FTC+EFV, and TFV+FTC+EFV combinations and synergistic HIV-1 RT inhibition at
the enzymatic level. We propose the molecular mechanisms for the TFV+FTC+EFV synergy to be a
combination of increased levels of the active metabolites TFV-DP and FTC-TP and enhanced DEC
formation by a chain-terminated DNA and HIV-1 RT in the presence of the second and the third drug in
the combination. This study furthers the understanding of the longstanding observations of synergistic anti-
HIV-1 effects of many NRTI+NNRTI and certain NRTI+NRTI combinations in cell culture, and provides
biochemical evidence that combinations of anti-HIV agents can increase the intracellular drug efficacy,
without increasing the extracellular drug concentrations.
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Background
Combination of anti-HIV agents has long been an indis-
pensable tool in fighting the AIDS epidemic. Combina-
tion of drugs from different classes has proven to be
beneficial in terms of sustained efficacy and long-term
safety, provided there are no significant negative pharma-
cokinetic drug-drug interactions. Among all of the anti-
HIV drugs in development or in the clinic, combinations
of nucleoside or nucleotide reverse transcriptase (RT)
inhibitor (NRTI) and non-nucleoside RT inhibitor
(NNRTI) have been the most extensively studied. NRTI
are transformed into their active tri- or diphosphate (TP or
DP) forms by cellular kinases [1]. Structurally resembling
the natural dNTPs, the active metabolites of NRTIs serve
as alternative substrates for HIV-1 RT during viral DNA
synthesis, which results in chain-termination of DNA
elongation due to the lack of the 3'-hydroxy moiety. The
incorporated NRTIs can be removed, however, by pyro-
phosphate- (PPi) or ATP-mediated excision that occurs at
a basal level for wild-type RT and can be accelerated or
diminished by different RT mutations, such as thymidine
analog mutations or K65R, respectively [2-4]. NNRTI
inhibit HIV-1 replication through multiple mechanisms
[5], but mainly by inducing conformational changes
within HIV-1 RT at the polymerase active site which signif-
icantly slow down viral DNA synthesis but have no effect
on the binding affinity of natural dNTP and primer/tem-
plate [6].
Many NRTI+NNRTI combinations show synergistic anti-
HIV activities in cell culture [7-12]. Synergistic effects were
also shown by drug combinations in HIV-1 RT enzymatic
assays [12-15]. The enhanced potency of the AZT+NVP
combination in comparison to AZT alone was reported in
a clinical trial study [16]. Two major mechanisms of syn-
ergy have been proposed: (1) NNRTI inhibited the PPi- or
ATP-mediated removal of zidovudine (AZT)-monophos-
phate (MP) from the 3'-end of the DNA primer [17-20];
and (2) NNRTI accelerated HIV-1 RT's RNase H activity
and thus diminished NRTI excision [21].
Interest in the NRTI+NRTI combinations was first ignited
during the HIV monotherapy era by the surprisingly syn-
ergistic effects of AZT+ddI both in vitro and in clinical trial
studies [22-24], in the absence of a pharmacokinetic inter-
action between the two drugs [25]. Additional in vitro
NRTI combination studies showed synergistic antiviral
activity in cell culture, including (but not limited to) AZT
+ either carbovir (CBV, the metabolite of abacavir (ABC)),
ddC, 3TC, FTC, or TFV [26-29], TFV+ddI [29], and
TFV+FTC [30]. To our knowledge, TFV+FTC synergy was
the only one that has been correlated with statistically sig-
nificant increases in the levels of the active metabolites
[30]. Most recently, a study on anti-HIV-1 synergy of a
panel of NRTI+NRTI combinations in peripheral blood
mononuclear cells (PBMC) claimed antagonistic effect of
TFV+ABC [31], contradicting an earlier report on the addi-
tive antiviral effect TFV+ABC tested in the same cell
line.[32]
The biochemical studies on the above mentioned syner-
gistic NRTI combinations have been somewhat controver-
sial, likely due to various experimental designs and
different methods of analysis. For example, using defined
sequences of RNA or DNA templates, White et al. reported
combinations of AZT-TP with ddCTP, ddATP, or CBV-TP
to be additive [33]. Also using a template with defined
sequence, Villahermosa et al. reported that the combina-
tion of AZT-TP and ddCTP was merely additive under con-
ventional conditions where the template:primer was in
large excess over the enzyme concentration; however,
when the enzyme was in large excess over the tem-
plate:primer, the combined inhibition effects of AZT-TP
and ddCTP were synergistic [34]. Periclou and colleagues
reported combinations of AZT-TP+ddATP and AZT-
TP+ddATP+3TC-TP synergistically inhibited HIV-1 RT,
based on a mathematic model in which the rate of DNA
synthesis was determined using the four natural dNTP
substrates and their competitive NRTI analogs [25].
There are many methods available to analyze the effect of
drug combinations [35-37]. Synergy and antagonism are
commonly defined as a greater or lesser pharmacological
effect than would be predicted for an additive effect.
Mathematically, there are two major definitions of addi-
tivity: Bliss Independence and Loewe Additivity. Bliss
Independence states that additivity occurs when two
agents act independently of the other. Loewe Additivity
defines the effects seen with a second drug present are the
same as that seen when a drug is added to itself; in other
words, when a drug is tested in combination with itself,
the observed effect is defined as additive. Among the
many frequently used methods, the median-effect
method by Chou and Talalay [38,39], the isobologram
analysis [40,41], and the Berebaum combination indices
[35] are based on Loewe Additivity, while the MacSynergy
II analysis [42] is based on Bliss Independence. All of
these four methods are accompanied with statistical anal-
yses. The Yonetani-Theorell Plot was first developed as a
simple graphical method to quantify the interaction of
two competitive inhibitors acting on the same enzyme
[43] and was later adopted to study drug combinations.
The combination of TDF, FTC, and EFV makes up the
components of the once-daily single tablet regimen (Atri-
pla) for treatment of HIV-1 infection [44]. In this paper,
we studied the drug combinations TFV+FTC, TFV+EFV,
FTC+EFV, and TFV+FTC+EFV in both cell-based assays
and HIV-1 RT enzymatic assays. We used different meth-
ods to analyze the effects of the combinations to mini-Retrovirology 2009, 6:44 http://www.retrovirology.com/content/6/1/44
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mize bias associated with a specific method. Furthermore,
we demonstrated that HIV-1 RT and TFV-terminated DNA
form dead-end complex (DEC) in the presence of FTC-TP,
which could contribute to the synergistic inhibition of
HIV-1 RT by TFV-DP+FTC-TP at the enzymatic level. Our
data also showed that EFV greatly facilitates the formation
of stable, DEC-like complexes with HIV-1 RT and TFV- or
FTC-MP-terminated DNA.
Results
Two- and three-drug combinations of TFV, FTC, and EFV 
showed synergistic anti-HIV activity in cell culture
TFV, FTC, and EFV were tested in two-drug and three-drug
combinations for antiviral activity against HIV-1 in MT-2
cells. The EC50 value for each single drug was 13 μM, 1.3
μM, and 5.6 nM for TFV, FTC and EFV, respectively. For
the median-effect analysis, combinations of TFV+FTC,
TFV+EFV, FTC+EFV, and TFV+FTC+EFV were synergistic,
as shown by the representative curves in Fig. 1 (panels A
to D) with calculated combination index (CI) values
below the additivity line (CI = 1), and with CI values of
0.52, 0.51, 0.59, and 0.56, respectively (Table 1).
For the MacSynergy analysis, combinations of TFV+FTC,
TFV+EFV, and FTC+EFV were strongly synergistic, as indi-
cated by the high peak of synergy above the flat plane of
additivity (Fig. 2A and 2B) and overall synergy volumes of
181 μM2% and 267 μM2%, respectively (Table 1). The
combination of FTC+EFV was moderately synergistic (Fig
1C) with a synergy volumes of 90 μM2% (Table 1).
For the isobologram analysis, the combinations of
TFV+FTC, TFV+EFV, and FTC+EFV are shown in Fig. 3
(panel A to C), where experimental data points are below
the calculated additivity line indicating synergistic effects
of the combinations. As summarized in Table 1, the com-
binations of TFV+FTC, TFV+EFV, and FTC+EFV were syn-
ergistic with ADA values of -0.37 (p = 0.001), -0.14 (p =
0.027), and -0.23 (p = 0.001), respectively. Overall, all of
the combinations of TFV, FTC, and EFV showed synergy,
and none of the combinations was antagonistic.
TFV-DP+FTC-TP combination showed synergistic 
inhibition of HIV-1 RT in enzymatic assays
An earlier study demonstrated a correlation between the
synergistic antiviral effect of TFV+FTC combination, and
the statistically significant increases in the levels of the
active metabolites in T-cell line CEM[30]. To investigate
whether the synergistic effect of TFV+FTC in cell culture
could also be translated into synergistic inhibition at the
enzymatic level, a standard HIV-1 RT inhibition assay was
performed under steady state conditions using drug con-
centrations across the physiological range. In patients'
peripheral blood mononuclear cells (PBMC) treated with
TDF or FTC, the TFV-DP and FTC-TP concentration are 0.5
μM and 5 μM, respectively and are well within the range
of the concentrations tested in the enzymatic assay
[45,46]. The IC50 values for TFV-DP, FTC-TP and EFV were
0.53 ± 0.08, 5.0 ± 3.2, and 0.12 ± 0.01 μM, respectively
when [α-32P]-dATP incorporation was used as the marker.
The IC50 values for TFV-DP, FTC-TP and EFV were 0.82 ±
0.23, 2.4 ± 0.8, and 0.12 ± 0.01 μM, respectively, when [α-
32P]-dCTP incorporation was used as the marker. The
combination of TFV-DP+FTC-TP was first analyzed by the
median-effect method. The combinations of TFV-
DP+TFV-DP and FTC-TP+FTC-TP were tested as experi-
mental controls, and as expected, they were additive
regardless of whether 32P-dATP or 32P-dCTP was used as
the radioactive marker in the assay (Table 2). The TFV-
DP+FTC-TP combination was tested at three fixed IC50
ratios 1:3, 1:1, and 3:1, which corresponded to molar
ratios of 1:30, 1:10, and 3:10, respectively. The results are
summarized in Table 2. The combination of TFV-
DP+FTC-TP was synergistic at all three IC50 ratios with CI
values in the range of 0.47–0.61, regardless of whether
32P-dATP or 32P-dCTP was used in the assay. A represent-
ative median-effect analysis plot for the TFV-DP+FTC-TP
combination is shown in Fig. 4A. In this experiment, TFV-
Table 1: Evaluation of drug combinations for inhibition of HIV-1 in MT-2 cell culture.
Combinations Analysis Method
Median-Effecta
(Combination Index)
MacSynergyb
(Synergy/Antagonism Volumes μM2%)
Isobologramc
(ADA, p value)
TFV+FTC synergy (0.52 ± 0.08) strong synergy (181 ± 30/-36 ± 10) synergy (-0.37, 0.001)
TFV+EFV synergy (0.51 ± 0.14) strong synergy (267 ± 50/-13 ± 5) synergy (-0.14, 0.027)
FTC+EFV synergy (0.59 ± 0.11) moderate synergy (90 ± 30/0 ± 10) synergy (-0.23, 0.001)
TFV+FTC+EFV synergy (0.56 ± 0.12) NDd ND
a The drugs were mixed at 1:1 IC50 ratios. Definition of the degrees of synergy is described in Methods. The values are averages of more than three 
independent measurements.
b Synergy/antagonism volumes were calculated at the 95% confidence level. Definition of the degrees of synergy is described in Methods.
c Synergy is defined by a negative ADA (the average deviation from dose-wise additivity) value with p value ≤ 0.05.
dND = not determined.Retrovirology 2009, 6:44 http://www.retrovirology.com/content/6/1/44
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DP and FTC-TP were combined at 1:1 IC50 ratio and the
combination was tested at eight concentrations. The line
at CI = 1 indicates the theoretical additive effect. It is evi-
dent that the combination of TFV-DP+FTC-TP had syner-
gistic inhibitory effect on HIV-1 RT since the calculated CI
for each of the eight drug combinations are well below 1.
To reduce the possibility of analysis bias, we further stud-
ied the combination of TFV-DP+FTC-TP using MacSyn-
ergy II analysis, which has been widely used to study drug
combinations [29,30,47,48]. The TFV-DP+FTC-TP combi-
nation was found to be additive with a synergy/antago-
nism volume of 0.63/-2.7, which was calculated at the
95% confidence interval (Table 3). The discrepancy
between the results from the median-effect analysis and
the MacSynergy II analysis led us to analyze the combina-
tion using three other methods: the isobologram analysis,
the Berebaum combination indices analysis with
weighted non-linear regression, and the Yonetani-Theo-
rell plots.
In the representative isobologram plot of the TFV-
DP+FTC-TP combination shown in Fig. 4B, the x-axis and
y-axis represent fractional inhibitory concentration (FIC)
of FTC-TP and TFV-DP, respectively. The calculated com-
bination effects, shown by closed circles with bi-direc-
tional error bars calculated from five replicates, are all
under the additivity line, indicating that the TFV-DP+FTC-
TP combination is synergistic (ADA value of -0.31; p =
0.002). The TFV-DP+FTC-TP combination was further
tested using analysis based on Berebaum Combination
Indices (CI) with weighted non-linear regression to study
the TFV-DP+FTC-TP combination. As shown in Fig. 4C,
the red bar indicates the 95% confidence interval and its
relative position to the CI50 = 1 line reveals the effect of
combination. The bar is to the left of the CI50 line, suggest-
ing synergy for the TFV-DP+FTC-TP combination (Table
3).
The Yonetani-Theorell plot was the method used by White
et al. to conclude that combinations of AZT-TP+ddCTP,
AZT-TP+ddATP, and AZT-TP+CBV-TP were all additive
when tested for inhibition of HIV-1 RT, even though all
these drug combinations were synergistic for inhibition of
HIV-1 in cell culture studies [33]. In our study, we used
this method to analyze the TFV-DP+FTC-TP combination
(Fig. 4D). For a range of TFV-DP concentrations (0–1.6
μM), the reciprocal of the ratio of initial rate over v (v0/v)
was plotted against the concentration of FTC-TP and the
data were fitted with linear regression. Synergistic inhibi-
tion was observed for the TFV-DP+FTC-TP combination,
as shown by the non-parallel and converging lines at the
left of the y-axis (Table 3).
TFV-DP+EFV combination showed synergistic inhibition of 
HIV-1 RT
To further understand the synergy of HIV-1 inhibition by
TFV+EFV in cell culture, the combination was tested at the
enzymatic level. The TFV-DP+EFV combination was tested
by using 32P-dATP only since the TFV-DP+FTC-TP combi-
nation using 32P-dATP or 32P-dCTP showed nearly identi-
cal results. The combination of TFV-DP+EFV was tested at
a 3:1, 1:1, and 1:3 IC50 ratios, which corresponded to 15:1,
5:1, and 5:3 molar ratios, respectively. As shown in Table
2, the combination of TFV-DP+EFV showed moderate
synergy at 3:1 ratios (CI = 0.69) and 1:1 IC50 ratios (CI =
0.75), and additivity at 1:3 IC50 ratio (CI = 0.94). This
combination was further tested using the three other
methods (Table 3): the MacSynergy II analysis indicated
that the combination showed minor synergy with a syn-
ergy/antagonism volume of (44/0); the isobologram anal-
ysis showed the combination to be synergistic with an
ADA value of -0.20 (p = 0.001); and the Yonetani-Theorell
plots of the combination demonstrated synergy (data not
shown).
FTC-TP+EFV combination showed synergistic inhibition of 
HIV-1 RT
To further understand the synergistic anti-HIV-1 effect of
FTC+EFV, the combination was evaluated at the enzy-
Synergistic inhibition of HIV-1 replication by combinations  TFV+FTC, TFV+EFV, FTC+EFV, and TFV+FTC+EFV ana- lyzed by the median-effect analysis Figure 1
Synergistic inhibition of HIV-1 replication by combi-
nations TFV+FTC, TFV+EFV, FTC+EFV, and 
TFV+FTC+EFV analyzed by the median-effect analy-
sis. The solid line presents curve fitting of the CI values as a 
function of fractional effect. The dashed lines represent 95% 
confidence interval. The line (in red) at CI = 1 represents 
additivity. (A) TFV+FTC (1:1 IC50 ratio) with an average CI of 
0.47; (B) TFV+EFV (1:1 IC50 ratio) with average CI of 0.54; 
(C) FTC+EFV (1:1 IC50 ratio) with an average CI of 0.62; (D) 
TFV+FTC+EFV (1:1:1 IC50 ratio) with an average CI of 0.46.Retrovirology 2009, 6:44 http://www.retrovirology.com/content/6/1/44
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matic level as well. The combination was tested using 32P-
dATP at 3:1, 1:1, and 1:3 IC50 ratios, which correspond to
150:1, 50:1, and 50:3 molar ratios, respectively. As shown
in Table 2, combination of FTC-TP+EFV showed synergy
at the 3:1 IC50 ratio and moderate synergy at the 1:1 and
1:3 IC50 ratios, with CI values of 0.61, 0.70, and 0.81,
respectively. This combination was further analyzed by
three other methods (Table 3): the MacSynergy II analysis
showed the combination showed minor synergy with a
synergy/antagonism volume of (41/-0.5); the isobolo-
gram analysis showed the combination was synergistic
with an ADA value of -0.14 (p = 0.002); and the Yonetani-
Theorell plots of the combination demonstrated synergy
(data not shown).
Triple drug combination TFV-TP+FTC-TP+EFV showed 
synergistic inhibition of HIV-1 RT in enzymatic assays
The HIV-1 RT inhibitory effects of triple drug combination
TFV-DP+FTC-TP+EFV were evaluated by the median-effect
analysis. Earlier studies of the two drug combinations
TFV-DP+FTC-TP at a 1:1 IC50 ratio showed synergy, there-
fore, TFV-DP: FTC-TP ratio was kept at a constant 1:1 IC50
ratio in this triple drug combination study. The combina-
tion was tested using 32P-dATP at 3:3:1, 1:1:1, and 1:1:3
IC50 ratios that correspond to 15:150:1, 5:50:1, and 5:50:3
molar ratios, respectively. This combination was synergis-
tic at all three IC50 ratios tested with CI value ranges from
0.37–0.67 (Table 2).
DEC formation by TFV-terminated DNA and FTC-MP-
terminated DNA
The dead-end complex (DEC) refers to a salt-stable com-
plex formed by HIV-1 RT/ddNMP-terminated DNA
primer-template bound to the next dNTP (or ddNTP) that
is resistant to being competed apart with excess template
[49,50]. When DEC forms, HIV-1 RT and the DNA
primer-template are "trapped" in a state where the for-
ward reaction (polymerization), backward reaction (ter-
minal ddNMP-excision), or enzyme-DNA dissociation
cannot occur. We investigated the DEC formation using
TFV-terminated DNA/RT/FTC-TP and FTC-MP-terminated
DNA/RT/TFV-DP to test the hypothesis that the incoming
NRTI might act as the next nucleotide to the chain-termi-
nated primer and form a DEC, thus stabilizing the pre-
existing chain-termination. Similarly, we speculated that
DEC formation by TFV- or FTC-MP-terminated DNA with
HIV-1 RT could be augmented in the presence of EFV,
which could play an important role in the mechanism of
action for the synergistic effects of TFV+EFV and FTC+EFV
combinations observed in cell culture and in HIV-1 RT
enzymatic assays. For these studies, formation of DEC was
determined by three kinetic constants including the disso-
ciation constant (Kd), the maximum percentage of DNA
primer-template forming a tight binding RT-DNA com-
plex (Bmax), and the ratio of Bmax/Kd which reflects the effi-
ciency of DEC formation. Furthermore, two sets of DNA
primer/templates (D20/D36 and D26/D50) were used to
address whether the observation was sequence-depend-
ent.
First, DEC formation using TFV-terminated DNA primer/
template and HIV-1 RT was tested in the presence the next
correct nucleotide dCTP or analogue FTC-TP. Along with
TFV-terminated DNA, ddAMP-terminated DNA was also
studied in parallel. As shown in Fig. 5a and Table 4, TFV-
terminated DNA was able to form DEC with RT in the
presence of dCTP or FTC-TP. Interestingly, TFV-termi-
nated DNA+RT formed DEC with incoming FTC-TP as
efficiently as with dCTP, but DEC formed with ddAMP-
terminated DNA+RT and FTC-TP 10-fold less efficiently
than with dCTP. Further observations showed that among
the NRTI combinations, ddAMP-terminated DNA+RT in
the presence of dCTP had the highest efficiency for DEC
formation in the NRTI as the next nucleotide experiments
(Bmax/Kd = 1.6 for D20/D36 and 6.9 for D26/D50).
Synergistic inhibition of HIV-1 replication by combinations of  (A) TFV+FTC, (B) TFV+EFV, and (C) FTC+EFV analyzed by  MacSynegy II Figure 2
Synergistic inhibition of HIV-1 replication by combi-
nations of (A) TFV+FTC, (B) TFV+EFV, and (C) 
FTC+EFV analyzed by MacSynegy II. Calculated addi-
tive antiviral interactions were subtracted from experimen-
tally determined values to reveal regions and corresponding 
concentrations at which synergistic antiviral interactions 
occurred. Peaks of statistically significant (95% confidence 
level) synergy are shown in colors from dark blue to red, 
with red indicating the strongest synergy. Values used to 
describe the percentage of inhibition above the expected 
were derived from five experiments.Retrovirology 2009, 6:44 http://www.retrovirology.com/content/6/1/44
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DEC formation using FTC-MP-terminated DNA primer/
templates was studied in the presence of the next correct
nucleotide dATP or analogue TFV-DP. As shown in Table
4, no DEC formation was detected for nearly all of the
FTC-MP-terminated DNA with nucleotides, with the
exception of the D27/D50-mer which showed low-level
DEC formation in the presence of dATP, mainly caused by
a very weak binding affinity (Kd = 862 μM) of dATP to the
RT-DNA complex. In contrast, ddCMP-terminated DNAs
were shown to form DEC in the presence of dATP or TFV-
DP, even though dATP induces 24- to 65-fold more effi-
cient DEC formation than TFV-DP.
Surprisingly, EFV strongly promoted a stable complex that
appeared biochemically DEC-like on all chain-terminated
primers tested (Fig. 5 and Table 4), and did so more effi-
ciently than with the natural dNTP, TFV-DP, or FTC-TP. In
the presence of EFV, TFV-terminated DNA+RT and
ddAMP-terminated DNA+RT formed stable complexes
with efficiencies that were more than 820- and 8.5-fold
higher than with dCTP, respectively. The TFV-terminated
DNA+RT formed complexes with EFV 4.8- to 7.8-fold
more efficiently than the ddAMP-terminated DNA+RT
with EFV. In addition, appreciable levels of complex for-
mation were detected for both FTC-MP and ddCMP-ter-
minated DNA in the presence of EFV, with the FTC-MP-
terminated DNA forming complexes 4.8- to 31-fold less
efficiently than ddCMP-terminated DNA. Similar observa-
tions were found with both sets of DNA pair primer/tem-
plates, although the longer DNA D26/D50 was shown to
be more efficient in forming complexes, which is in agree-
ment with a previous report on DEC [51].
Discussion
In this study, NRTI+NRTI and NRTI+NNRTI drug combi-
nations were investigated using cell-based antiviral assays,
HIV-1 RT enzymatic inhibition assays, and gel shift exper-
iments. Even though many studies have shown the syner-
gistic effect of NRTI combinations in cell culture, a few
enzymatic studies suggested that these combinations
inhibit HIV-1 RT additively [33,34]. These findings were
readily accepted since it is conceptually hard to under-
stand how two inhibitors that share the same mechanism
of action could act synergistically. In 2006, our group
reported the synergistic antiviral effect of TFV+FTC combi-
nation in cell culture studies and its correlation with ele-
vated levels of the active metabolites of each drug [30].
In the current paper, we analyzed the TFV+FTC combina-
tion in cell culture using three methods including the
median-effect, MacSynergy II, and the isobologram analy-
sis, where the results showed synergistic effects, and were
consistent with our earlier report [30]. The new studies
include enzymatic experiments where five different analy-
ses were used: the median-effect, MacSynergy II, isobolo-
gram, Berebaum combination indices, and the Yonetani-
Theorell Plot analysis. Four of the five analyses showed
that the combination of TFV-DP+FTC-TP led to synergistic
inhibition of HIV-1 RT, with the exception of the MacSyn-
ergy II analysis, which showed the TFV-DP+FTC-TP com-
bination to be additive. Interestingly, when the relevant
subset of the same raw data which was found to be addi-
tive by the MacSynergy II analysis was re-analyzed with
the median-effect analysis, isobologram analysis and the
Yonetani-Theorell Plot analysis, all of the results showed
the TFV-DP+FTC-TP combination to be synergistic. The
discrepancy between the MacSynergy II and other analysis
could be due to the fact that each method has its own sta-
tistical threshold, and the MacSynergy II analysis could
have a more stringent criterion on calling whether the
observed effect is synergistic. Whether the differences
between the mathematic models of Bliss Independence
and Loewe Additivity contribute to this discrepancy is
beyond the scope of this study.
The molecular mechanism of action for the synergistic
effects at the enzymatic level by two NRTIs remained
unknown. NRTIs with differing base moieties should
chain-terminate different sequences, but this would not
explain synergy at the enzymatic level. Based on the
reports that DEC can be formed by the assembly of 3'-ter-
minated DNA, HIV-1 RT, and the next incoming natural
Synergistic inhibition of HIV-1 replication by drug combina- tions analyzed by the isobologram analysis Figure 3
Synergistic inhibition of HIV-1 replication by drug 
combinations analyzed by the isobologram analysis. 
(A) The combination of TFV+FTC with an ADA value of -
0.37 (p < 0.001); (B) The combination of TFV+EFV with an 
ADA value of -0.14 (p < 0.03); (C) The combination of 
FTC+EFV with an ADA value of -0.23 (p < 0.001). The diago-
nally drawn solid line (in red) represents additivity.Retrovirology 2009, 6:44 http://www.retrovirology.com/content/6/1/44
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dNTP or ddNTP [49-52], we hypothesize these NRTIs can
sequester the viral DNA and HIV-1 RT in this inactive
form, protect the NRTI-terminator from excision, and
therefore enhance the inhibition of viral DNA synthesis
introduced initially by the terminating NRTI. Our results
showed that, using two different sequence contexts, FTC-
TP could form DEC with TFV-terminated DNA+RT at lev-
els that are equal to or 3.9-fold more efficient than dCTP.
The relatively high intracellular concentration of FTC-TP
(5 μM) in patients [46] relative to dCTP (0.7–23.2 μM)
[53,54] suggests that our in vitro study is physiologically
plausible. Our results are consistent with a recent report
on the formation of DEC by TFV-terminated
DNA+RT+dCTP, even though our reported Kd values (179
μM) are notably higher than the 1–5 μM reported values
[51,55]. However, our results are more in line with other
reported values [50,52]. This discrepancy could be due to
primer/template sequence effects which are known to sig-
nificantly affect the Kd values, different salt concentrations
(60–160 mM KCl), and different times of incubation (15
min to 60 min) applied in each assay. Similar to a report
on the lack of DEC formation by a 3TC-MP-terminated
primer [50], we observed low-level DEC formation by
FTC-MP-terminated DNA with dATP and no DEC forma-
tion with TFV-DP.
The observation that the ddAMP-terminated DNA+RT
formed DEC more efficiently than the TFV-terminated
DNA+RT with a dNTP or NRTI as the incoming nucleotide
is consistent with the favorable binding of natural dNTP
over ddNTP. Site-specific footprinting experiments in low
dNTP concentrations showed that ddAMP-terminated
primers existed predominantly in the post-translocational
state which favors DEC formation, while TFV-terminated
primers existed equally in both pre- and posttransloca-
tional states and formed a DEC less favorably than
ddAMP [55]. A similar trend was observed by Tong et al.
where the preference of natural dNTP over ddNTP for
DEC formation was reported [51].
An unexpected observation was that TFV-terminated DNA
and FTC-TP formed DEC as efficiently or 4-fold higher
than with dCTP. Structurally, the smaller and more flexi-
ble TFV at the primer terminus, driven by the absence of a
cyclic sugar, might better accommodate the binding of
FTC-TP compared to a ddAMP-terminated primer. It may
also be possible that the terminal-TFV and incoming FTC-
TP may adopt a conformation that more strongly favors
the posttranslocational state. There are no reported stud-
ies on the translocation state of FTC-MP-terminated prim-
ers, but it is conceivable that the L-conformation of FTC
Table 2: Combination Index (CI) values of TFV-DP, FTC-TP and EFV combination studies in the HIV-1 RT enzymatic assay.
Drug Combinations 32P-labeled dNTP Ratioa Average CI ± SDb Degree of Synergyc
TFV-DP+TFV-DP dATP 1:1 0.93 ± 0.07 additive
FTC-TP+FTC-TP dATP 1:1 1.09 ± 0.28 additive
dCTP 1:1 1.09 ± 0.25 additive
TFV-DP+FTC-TP dATP 3:1 0.59 ± 0.04 synergy
1:1 0.47 ± 0.09 synergy
1:3 0.47 ± 0.04 synergy
dCTP 3:1 0.60 ± 0.18 synergy
1:1 0.61 ± 0.11 synergy
1:3 0.47 ± 0.11 synergy
TFV-DP+EFV dATP 3:1 0.69 ± 0.01 moderate synergy
1:1 0.75 ± 0.04 moderate synergy
1:3 0.94 ± 0.08 additive
FTC-TP+EFV dATP 3:1 0.61 ± 0.08 synergy
1:1 0.70 ± 0.03 moderate synergy
1:3 0.81 ± 0.01 moderate synergy
TFV-TP+FTC-TP+EFV dATP 3:3:1 0.37 ± 0.08 synergy
1:1:1 0.49 ± 0.10 synergy
1:1:3 0.67 ± 0.18 synergy
a The ratio represents the biologically relevant IC50 ratios of the two compounds that were combined, based on their individual IC50s determined in 
the HIV-1 RT assay.
b The averages and standard deviations were calculated from the results of at least three independent measurements.
c Definition for degree of synergy is described in Methods.Retrovirology 2009, 6:44 http://www.retrovirology.com/content/6/1/44
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severely disfavors the translocation of FTC-MP-terminated
primer to the posttranslocational state and thereby pre-
cludes the formation of DEC. Our experimental data
showed that FTC-MP-terminated DNA only formed low-
levels of DEC in the presence of dATP, and no DEC in the
presence of TFV-DP, while ddCMP-terminated DNA
formed DEC with dATP or TFV-DP.
Combinations of NRTI+NRTI at the enzymatic level
should be studied with a system carefully designed to be
heterogeneous enough to reflect the "independent" incor-
poration of each single NRTI. In our assay, the activated
calf thymus DNA was used instead of a DNA primer/tem-
plate with defined sequence that might pre-condition the
order of incorporation and bias the outcome [33,34]. It is
noteworthy that TFV-DP could also induce a DEC with
TFV-MP-terminated DNA/RT provided dATP is the next
correct dNTP; however, this effect on "enhancing" RT
inhibition is inseparable from the enzyme inhibition
caused by chain-termination alone. In other words, an
added effect (synergy) will not be observed when TFV-DP
is added to itself.
A second focus of this paper analyzes the NRTI+NNRTI
(two drug class) combinations of TFV+EFV and FTC+EFV
using three different methods of analysis: the median-
effect, the MacSynergy II, and the isobologram. All of
these analyses showed that the TFV+EFV and FTC+EFV
combinations synergistically inhibited HIV-1 replication.
Furthermore, it was demonstrated that the combination
of TFV-DP+EFV and FTC-TP+EFV are synergistic at the
enzymatic level, and that both TFV-terminated and FTC-
MP-terminated DNA formed stable, DEC-like complexes
with HIV-1 RT in the presence of EFV. The Kd values for
EFV binding for stable complex formation was around 1
μM, which is well below the 5 μM steady-state plasma EFV
concentration [56]. Our findings are consistent with the
report by Cruchaga et al. on the formation of a stable com-
plex by HIV-1 RT, AZT-terminated template-primer and
EFV [19].
Based on our current study and the previously reported
findings, we propose that there are at least three inde-
pendent factors may contribute to synergistic effects of
NRTIs and NNRTIs: (1) diminished ATP binding in the
presence of NNRTIs decreases efficiency of excision for
NRTI terminator [18,20]; (2) increased RNase H activity
in the presence of NNRTIs can diminish opportunities for
NRTI excision [21]; and (3) as shown in our work, NNRTI-
mediated stable complex formation prolongs and
enhances the chain-termination effects of NRTIs.
Remarkably, EFV induces stable complexes substantially
more efficiently than the next base-paring dNTP or NRTI-
TP (or -DP). Complexes formed with EFV may be far less
sensitive to the translocational state of the chain-terminat-
ing NRTI than traditional DEC formed with dNTP or
ddNTP. Furthermore, EFV formed complexes independ-
ently of the sequence of the next correct base, which
restricts DEC formation by a nucleotide. The EFV-based
complexes should be structurally distinct from the DEC
formed by an incoming nucleotide. Additional insight on
the structure of this complex was recently put forth by
Abbondanzieri et al., where HIV-1 RT bound to chain-ter-
minated polypurine track DNA in the presence of the
Synergistic inhibition of HIV-1 RT by TFV-DP+FTC-TP com- bination analyzed by different methods Figure 4
Synergistic inhibition of HIV-1 RT by TFV-DP+FTC-
TP combination analyzed by different methods. (A) 
The median-effect analysis where the solid line presents 
curve fitting of the CI values as a function of the fractional 
effect. The red line at CI = 1 represents additivity. The 
dashed lines represent 95% confidence interval. TFV-DP and 
FTC-TP are combined at 1:1 IC50 ratios (1:10 molar ratios) 
with an average CI value of 0.47; (B) The isobologram analy-
sis where the diagonally drawn solid line (in red) represents 
additivity. Average deviation from dose-wise additivity was -
0.43 (p = 0.001), indicating a synergistic effect of the combi-
nation; (C) The Berenbaum combination indices analysis 
where the open circles are data from five experiments and 
the solid line represents the CI line. The red bar at the CI50 
indicates the 95% confidence intervals. The bar is to the left 
of the CI50 = 1 line, indicating synergy for this combination. In 
this experiment, TFV-DP and FTC-TP were combined at 1:4 
IC50 ratios (1:40 molar ratios); (D) The Yonetani-Theorell 
plot where FTC-TP was tested as the "first drug" and TFV-
DP was added as the "second drug" at the following concen-
trations: (black circle) 0 μM, (open circle) 0.1 μM, (black tri-
angle) 0.2 μM, (open triangle) 0.4 μM, (black square) 0.8 μM, 
and (open square) 1.6 μM. The Yonetani-Theorell plot shows 
the lines are converging at the left of the y-axis and the 
slopes of the lines increased with TFV-DP concentration, 
indicating the combination was synergistic.Retrovirology 2009, 6:44 http://www.retrovirology.com/content/6/1/44
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NNRTI nevirapine (or EFV) showed increased RT/DNA
association/binding time and "flipping" between
polymerase- and RNase H-binding orientations, where
the RNase-H/non-polymerase binding orientation was
favored [57]. This nevirapine-based complex therefore
showed a distinct pattern of binding orientations com-
pared to a traditional DEC bound with dNTP where only
the polymerase-competent binding orientation is
observed. In either binding orientation, the EFV-based
complex appears to be a DEC-like complex that is stable
in the presence of high salt concentration and competing
DNA, where the chain-terminated primer terminus pre-
sumably lies inaccessible to excision. Grobler et al.
showed that NNRTIs potently and specifically inhibit
plus-strand initiation and proposed that part of the
NNRTI inhibition on HIV-1 RT-catalyzed polymerization
is the result of trapping the enzyme in a polymerase-inde-
pendent RNase H-competent mode of binding [58]. Our
study demonstrated that part of the NNRTI inhibition
may also come from the trapping of enzyme once the
primer is terminated with a NRTI.
It is worth noting that even though EFV promoted DEC
formation at a much higher level than TFV-DP or FTC-TP,
drug combinations involving EFV did not yield a higher
degree of synergy than the combination of TFV-TP+FTC-
TP. It is possible that additional factors may come into
play.
Conclusion
In summary, the combinations of TFV+FTC, TFV+EFV,
FTC+EFV, and TFV+FTC+EFV all showed synergistic anti-
HIV activity in cell culture and synergistic inhibition of
HIV-1 RT under steady state enzymatic kinetic conditions.
Gel shift experiments suggest the efficient formation of
DEC of RT/TFV-terminated DNA/FTC-TP, and DEC-like
complexes of RT/TFV-terminated DNA/EFV and RT/FTC-
MP-terminated DNA/EFV. We propose the following
mechanisms contributing to the TFV+FTC+EFV synergy:
(1) TFV+FTC combination results in increased levels of
the active metabolites TFV-DP and FTC-TP [30]; and (2)
DEC or DEC-like complex formation by TFV-terminated
DNA and HIV-1 RT in the presence of the FTC-TP or EFV,
and by FTC-MP-terminated DNA and HIV-1 RT in the
presence of EFV. This study furthers our understanding of
the mechanism of action for anti-HIV drug interactions
and the efficacy observed for the TDF+FTC+EFV triple
combination for the treatment of HIV infection.
Methods
Reagents
TFV, FTC, and EFV were synthesized by Gilead Sciences.
All four natural dNTPs, ddATP, ddCTP, and [α-32P]dATP,
[α-32P]dCTP, and [γ-32P]ATP were from GE Healthcare
BioSciences (Piscataway, NJ). TFV diphosphate (TFV-DP)
and FTC triphosphate (FTC-TP) were synthesized by
ChemCyte, Inc. (San Diego, California, USA) as lithium
salt, was > 95% pure by HPLC, and free of inorganic phos-
phate confirmed by 31P-NMR. Activated calf thymus DNA
and poly(rA).poly(dT)12–18  were purchased from GE
Healthcare BioSciences (Piscataway, New Jersey, USA).
DNA oligonucleotide primers D19 (5'-GTCCCTGTTCG-
GGCGCCAC), D25 (5'-CTGAGACAACATCTGCTGAGG-
TAGG), and D26 (5'-CTGAGACAACATCTG CTGAGGTA
GGA), and templates D36A (3'-CGAAAGTCCAGGGA CA
AGCCCGCGGTG TGTATCTCT), D36C (3'-CGAAAGTC-
Table 3: Analyses of TFV-DP, FTC-TP and EFV combination studies in the HIV-1 RT enzymatic assaya.
Analysis Methods Drug Combinations
TFV-DP+FTC-TP TFV-DP+EFV FTC-TP+EFV
Median-effect
(CI value)
synergya
(0.47 ± 0.09)
moderate synergy (0.75 ± 0.04) moderate synergy (0.70 ± 0.03)
MacSynergy IIb
(synergy/antagonism volume)
additive
(0.63 ± 1.2/-2.7 ± 3.4)
minor synergy
(44 ± 20/0 ± 0)
minor synergy
(41 ± 15/-0.5 ± 1.1)
Isobologram
(ADAc, p value)
synergy
(-0.43, 0.001)
synergy
(-0.20, 0.001)
synergy
(-0.14, 0.002)
Berenbaum Combination Indices synergy NDd ND
Yonetani-Theorell Plots synergy synergy synergy
a Definition for degree of synergy (whenever applicable) is described in Methods.
b The volumes are calculated at the 95% confidence interval. The values are averages from 3 to 4 independent measurements. Five parallel repeats 
were tested in each measurement.
c ADA = average deviation from additivity
d ND = not determined.Retrovirology 2009, 6:44 http://www.retrovirology.com/content/6/1/44
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CAGGGACAAGCCCGCGGTG GTAATCTCT), and D50
(3'-GACTCTGTTGTAGACGACTCCATCC TGTATGGTGT-
GCTGTGGTGTGCTGT) were prepared and PAGE purified
by Integrated DNA Technologies, Inc. (Coralville, Iowa,
USA). The underline base indicates the template base for
the incoming dNTP. Concentrations of oligonucleotides
were determined from the absorbance at 260 nm. XTT
{(2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phe-
nylamino) carbonyl]-2H-tetrazolium hydroxide} was
from Sigma-Aldrich (St. Louis, Missouri, USA).
Recombinant HIV-1 RT enzyme construction and 
purification
Wild-type HIV-1 RT p66/p51 heterodimers containing N-
terminal 6-His tags were cloned and purified as previously
described [3]. The active site concentration was 52% for
HIV-1 RT determined by pre-steady state kinetic analysis
[59].
Antiviral combination assays
Human T leukemia MT-2 cells were obtained from the
NIH AIDS Research & Reference Reagent Program and
were maintained in RPMI 1640 media supplemented with
10% FBS, 50 μg/mL gentamicin and 0.29 μg/mL
glutamine. MT-2 cells were infected with HIV-1 strain
xxLAI [60] at a multiplicity of infection of 0.03 for 3 hrs,
washed once with complete media, and plated at a final
concentration of 3 x104 cells/well in 96-well plates con-
taining various concentrations of test compound. The
infected cells were incubated for 5 days at 37°C in 5%
CO2. Antiviral activity was measured by determining the
HIV-1 cytopathic effect by using the vital dye XTT (2,3-
bis(2-methoxy-4-nitro-5-sulphophenyl)-2H-tetrazolium-
5-carboxanilide) based colorimetric assay [61]. TFV, FTC,
and EFV were first tested individually for effective concen-
trations which inhibited 50% of viral replication (EC50)
using SigmaPlot 9.0 (Systat Software Inc., San Jose, CA).
For the median-effect analysis, the compounds were com-
bined at a 1:1 ratio based on their EC50. Six to eight con-
centrations of each single drug, two-drug combinations,
and three-drug combinations were assayed in at least
three independent experiments with quadruplicate wells
for each experiment. The triple drug combination of
Table 4: Formation of DEC or DEC-like complex by ddNTP-terminated DNA and HIV-1 RT in the presence of next correct dNTP, 
ddNTP or EFV.
Dideoxyadenosine analog as the chain-terminator
Next Correct dNTP or ddNTP EFV
DNA Terminator dCTP FTC-TP
Kd (μM) Bmax (%) Bmax/Kd Kd (μM) Bmax (%) Bmax/Kd Kd (μM) Bmax (%) Bmax/Kd
D20/D36 TFV 232 ± 12a 18.5 ± 6.7 0.079 250 ± 11 17.7 ± 3.9 0.071 0.70 ± 0.10 45.7 ± 10.0 65
ddAMP 21.5 ± 9.8 34.2 ± 4.6 1.6 171 ± 28 28.1 ± 4.7 0.16 1.20 ± 0.38 16.3 ± 3.5 13.6
D26/D50 TFV 179 ± 33 50.0 ± 5.5 0.28 46.5 ± 7.8 50.0 ± 5.0 1.1 1.22 ± 0.28 44.4 ± 3.7 36
ddAMP 8.1 ± 2.1 55.8 ± 3.4 6.9 86.8 ± 0.2 60.2 ± 7.2 0.69 2.42 ± 1.10 11.2 ± 0.6 4.6
Dideoxycytidine analog as the chain-terminator
Next Correct dNTP or ddNTP EFV
DNA Terminator dATP TFV-DP
Kd (μM) Bmax (%) Bmax/Kd Kd (μM) Bmax (%) Bmax/Kd Kd (μM) Bmax (%) Bmax/Kd
D20/D36 FTC-MP NDa ND ND ND ND ND 1.54 ± 0.33 5.53 ± 1.83 3.0
ddCMP 16.9 ± 8.5 38.0 ± 4.4 2.2 445 ± 114 15.3 ± 2.7 0.034 1.03 ± 0.25 14.9 ± 0.8 14.5
D27/D50 FTC-MP 862 ± 229 45 ± 14 0.052 ND ND ND 1.26 ± 0.24 3.96 ± 1.55 3.1
ddCMP 6.5 ± 2.6 60 ± 3 9.2 140 ± 19 55 ± 2 0.39 0.11 ± 0.06 10.6 ± 2.0 96
All Values reported are average ± standard deviation from at least three measurements.
aND = No DEC formation was detected at the highest concentration (2 mM) tested.Retrovirology 2009, 6:44 http://www.retrovirology.com/content/6/1/44
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TFV+FTC+EFV was studied by the median-effect analysis
only. The triple drug combination of TFV+FTC+EFV was
studied by the median-effect analysis only. For the Mac-
Synergy analysis, combinations of TFV+FTC, TFV+EFV,
and FTC+EFV were tested in a checkerboard fashion in 96-
well plates with the starting concentration for each com-
pound fixed at three-fold to four-fold above the EC50
value. For the isobologram analysis, combinations of
TFV+FTC, TFV+EFV, and FTC+EFV were tested in a check-
erboard fashion with the starting concentration for each
compound fixed at three-fold to four-fold above the EC50
value.
HIV-1 RT enzymatic combination assay
All concentrations listed were final except noted other-
wise. All RT reactions were conducted as follows: A solu-
tion (buffer A) containing 50 mM Tris-HCl, 5 mM MgCl2,
60 mM KCl, 5 mM DTT, 4.2% (v/v) glycerol, 300 μg/mL
bovine serum albumin, 400 nM dATP, 400 nM dCTP, [α-
32P]dATP (or [α-32P]dCTP, 0.03 μCi/μL), various concen-
trations of each single inhibitor (or their combinations)
and 5 nM HIV-1 RT was pre-incubated at 37°C for 5 min.
The reaction was initiated by mixing buffer A with a pre-
incubated mixture (buffer B) of 50 μM dGTP, 50 μM TTP,
and 3 mAU/μL activated calf thymus DNA. The 75 μL
reaction mixture was incubated at 37°C and 5 μL aliquots
were removed and spotted onto Whatman DE81 anion
exchange paper at 1, 1.5, 2, 2.5, and 3 min time interval
(for fixed-ratio setup [62] or at a single time point 3 min
(for checkerboard setup [42]. After washing with
Na2HPO4 buffer (50 g/L, 3 × 5 min), distilled water (5
min) and ethanol (5 min), the paper was air-dried and
exposed to a phosphor storage screen. Product formation
was quantified using GE Storm 820 PhosphorImager and
ImageQuant TL software (GE Healthcare, Piscataway,
New Jersey, USA). The observed rate for the HIV-1 cata-
lyzed reaction was quantified by linear regression of the
product formed as a function of time (Kaleidagraph, 4.0,
Synergy Software, Reading, Pennsylvannia, USA). Less
than 2% substrate was consumed in the time frame tested.
For each inhibitor concentration, percentage inhibition
was calculated by using no-drug as 0% inhibition. The
IC50 values were calculated using Sigma Plot 9.0 (Systat
Software, San Jose, California, USA).
Drug combination data analysis
Median-effect analysis
The degrees of synergy and antagonism were determined
using CalcuSyn software (version 2.0, Biosoft, Cambridge,
UK) which is based on median-effect principle by Chou
and Talalay [62]. In this analysis, the log (fa/fu) is plotted
as a function of the log [I], where fa is the fractional inhi-
bition caused by the drug relative to the no drug control,
fu is the fractional uninhibited level (1-fa), and [I] is the
drug concentration. The IC50 value is calculated from the
y-intercept (-m * log IC50), where m is the slope of the
curve. The following equation represents how the combi-
nation index (CI) is defined in a mutually exclusive
model:
Where 1 and 2 represent the individual action of drug 1 or
drug 2, while 1,2 represents the combined action of the
drug combination. The CI values of < 1, = 1, and > 1 indi-
cate synergy, additive effect, and antagonism, respectively.
The degree of synergy is categorized based on the CI value:
very strong synergy (< 0.1), strong synergy (0.1 to 0.3),
synergy (0.3 to 0.7); moderate synergy (0.7 to 0.85), addi-
tive (0.85 to 1.20), moderate antagonism (1.20 to 1.45),
CI
fa fu
fa fu
fa fu
fa fu
=+
()
() ,
()
() ,
1
12
2
12
DEC formation by HIV-1 RT, TFV-terminated DNA 26/50- mer Figure 5
DEC formation by HIV-1 RT, TFV-terminated DNA 
26/50-mer. (A) DEC formation by dCTP, FTC-TP, or EFV 
analyzed on a 6% non-denaturing polyacrylamide gel. (B) 
Quantification of the DEC formed by TFV-terminated DNA 
with HIV-1 RT in the presence of dCTP, FTC-TP, or EFV. 
Please note that the EFV x-axis is scaled significantly different 
from dCTP and FTC-TP. The amounts of free primer/tem-
plate and DEC where quantified, and the percentage of DEC 
formed was plotted as a function of the concentration of 
dCTP, FTC-TP, or EFV. The solid line represents curve fitting 
of the data using the single ligand binding equation y = (Bmax × 
[ligand])/(Kd + [ligand]). The DEC formation by TFV-termi-
nated DNA/RT in the presence of dCTP yielded Bmax = 49.2 
± 2.7% and Kd = 185 ± 28 μM (left panel); The DEC forma-
tion by TFV-terminated DNA/RT in the presence of FTC-TP 
with Bmax = 50.4 ± 1.1% and Kd = 52.6 ± 3.4 μM (middle 
panel); The DEC formation by TFV-terminated DNA/RT in 
the presence of EFV with Bmax = 48.0 ± 2.7% and Kd = 1.43 ± 
0.25 μM (right panel).Retrovirology 2009, 6:44 http://www.retrovirology.com/content/6/1/44
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antagonism (1.45 to 3.3), strong antagonism (3.3 to 10),
and very strong antagonism (> 10). The 95% confidence
interval at each level of fractional inhibition (fa) is calcu-
lated by the formula: CI ± (1.96 × S.D.), where the values
CI + (1.96 × S.D.) and CI - (1.96 × S.D.) correspond to the
upper and lower boundaries of the confidence interval,
respectively.
All drug combinations were tested at increasing total drug
concentrations that were set at fixed 1:1 ratios based on
the single drug IC50 values for cell-based combination
assays. For HIV-1 RT enzymatic assays, two drug combina-
tions were tested using three series of experiments with
increasing total drug concentrations that remained fixed
at IC50 ratios of 1:3, 1:1, and 3:1, while the three drug
combination TFV-DP+FTC-TP+EFV experiments were
tested at 3:3:1, 1:1:1, and 1:1:3 fixed IC50 ratios. Each drug
ratio experiment was repeated at least three times and for
each experiment a set of CI values was reported at 50%,
75%, 90% and 95% (EC50, EC75, EC90, EC95) inhibition
levels. In many cases, the CI value decreased as the frac-
tional inhibition (fa) increased, as commonly seen in
many synergistic combinations. Therefore, the averaged
CI values at EC50, EC75, EC90, and EC95 were used as rec-
ommended by the program manual. In some occasions
when the effect of one single drug did not reach the 95%
inhibition level, the EC95 value for the combination was
not included for the average CI calculation. Data points
that reach > 99% inhibition were excluded from the anal-
ysis.
MacSynergy II analysis
The MacSynergy II program (version 1.0, Ann Arbor, MI)
calculates a theoretical additive value for each drug com-
bination based on the values generated by the drugs alone
using the Bliss Independence model [42]. The theoretical
additive values are subtracted from the experimental val-
ues generated by each drug combination to give a value of
synergy (positive value) or antagonism (negative value).
These synergy and/or antagonism values are plotted on a
three-dimensional graph with their corresponding drug
combinations. Areas of the graph blow zero indicate
antagonism, whereas areas above zero indicate synergy. A
synergy volume is calculated by adding all of the positive
values for each drug combination. Similarly, all of the
negative values are added to give an antagonistic volume.
These synergy and antagonism volumes are then statisti-
cally evaluated using the 95% confidence level and are
expressed in μM2%, which are used to categorize the
degree of synergy: strong synergy (>100), moderate syn-
ergy (50 to 100), minor synergy (25 to 50), additive (-25
to 25), minor antagonism (-25 to -50), moderate antago-
nism (-50 to -100), and strong antagonism (< -100) [63].
In our cell culture study, the score of synergy/antagonism
was calculated from a set of 5 replicate parallel measure-
ments and more than 3 sets of such experiments were con-
ducted to test the reproducibility of the results.
Compounds were tested in a checkerboard fashion in 96-
well plates with the starting concentration for each com-
pound fixed at threefold to fourfold above the EC50 value.
Compound #1 was tested at 8 concentrations with 2-fold
serial dilutions down the plate, while compound #2 was
tested at 12-concentrations with 2-fold serial dilutions
across the plate. The concentration range of the individual
drugs was carefully selected to ensure that the inhibition
by each drug remained <95% at the highest concentra-
tion. It is known that when single drug reaches >95% inhi-
bition, any additive or synergistic effect of drug
combination can no longer be detected and the effect is
often scored as antagonism [63].
The enzymatic study was conducted in a similar manner,
where synergy was calculated from a set of 5 parallel meas-
urements and 3–4 independent sets of experimental data
were collected. The starting concentration for each com-
pound was fixed at 3–4 fold above the individual drug
IC50 value.
Isobologram analysis
The isobologram analysis is a graphical approach that can
be traced back to as early as the eighteen century [35], and
is time-tested and widely accepted [40]. The combination
studies are generally conducted using a checkerboard
setup where dose-response curves are generated for each
drug alone and in combination and used to determine
EC50 values for each drug alone or in the presence of the
fixed concentration of the second drug using GraphPad
Prism (version 4.0, Systat Software Inc., San Jose, Califor-
nia, USA). Fractional inhibitory concentrations are calcu-
lated by dividing the EC50 of drug 1 with a fixed overlay of
drug 2 by the EC50 of drug 1 alone (the x-coordinate). The
y-coordinate is the fixed concentration of drug 2 divided
by the EC50 of drug 2 alone. These points are plotted on a
graph to generate the isobologram. On the same graph, a
diagonally drawn line represents "additivity" by linking
coordinates (1, 0) to (0, 1) (Fig 3B). Data points that are
above the additivity line represent antagonism between
the compounds whereas data points below the additivity
line represent synergy between the compounds. The
intensity of the interaction can be measured by the statis-
tical difference from dose-wise additivity tested by a one-
tailed  t-test [41]. The average deviation from additive
(ADA) is reported with a p value. A negative ADA value
indicates synergy and a value of -0.5 indicates strong syn-
ergy, however there isn't a clearly defined scoring system
for synergy analyzed by quantitative isobologram [41];Retrovirology 2009, 6:44 http://www.retrovirology.com/content/6/1/44
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therefore, we defined combinations with ADA values
between 0 to -0.5 to be synergistic, as long as the values
were statistically significant (p < 0.05).
Berenbaum combination indices approach
The Berenbaum combination (or interaction) indices
method [64] is mathematically identical to the isobolo-
gram analysis described earlier. The experimental condi-
tion is very similar to the ones used in fixed ratio assays,
but a single 5-minute time point was collected for each
reaction due to the requirement of large data collection.
The product formation at 5 min is within the linear range
of the assay. A total of 5 different fixed-ratio combinations
of the two drugs (1:1, 1:2, 2:1, 1:4, and 4:1 EC50 ratio),
plus each agent alone, and 88 design points in quintupli-
cate for a total of 440 data points were used in the mode-
ling. The analysis started with modeling of the error
structure and calculation of variance and means for each
of the 88 sets of 5 replicates and derived weighting factor
for subsequent nonlinear regression runs. Next, the data
for each single agent and the five different fixed-ratio com-
binations were fitted to the four parameter Hill equation
(see below) with transformed x-axis (C1/IC50 +C2/IC50)
with iteratively reweighed nonlinear regression using SAS
v. 9.1 NLIN. The value represented by C1/IC50 + C2/IC50 is
CI50, which is equal to the combination indices at the IC50
level and is a measure of synergy (CI50 < 1), or additivity
(CI50 = 1), or antagonism (CI50 > 1). As shown in Figure
3C, the red bar indicates the 95% confidence interval and
its relative position to the CI50 = 1 line reveals the effect of
combination. When the bar is to the left of the CI50 line,
synergy is indicated; when the bar is to the right, antago-
nism is indicated; and when the bar crosses the CI50 = 1
line, additivity is indicated.
Where E is the output (effect or response), and C is the
input (concentration of agent). The Econ parameter is the
level of measured effect at zero drug concentration; the B
background parameter is the level of measured effect at
infinite drug concentration; and m is called the Hill sig-
moidicity or slope parameter.
Yonetani-Theorell plot
The Yonetani-Theorell plot approach has been used by
many groups in the past to study antiretroviral drug com-
binations [33,65-67]. Even though it was a popular choice
in the 1980's-1990's, Yonetani-Theorell Plot is known
today for oversimplifying and misinterpretation for cer-
tain drug combination studies [68]. However, this
method was used in our study to provide a way to com-
pare our analysis with previous published studies where
the Yonetani-Theorell plot analysis was the only method
employed. In the absence of the second drug, the recipro-
cal of the ratio of the initial rate in the absence of inhibi-
tors over v (v0/v) is plotted against the concentration of
first drug and the data are fitted with linear regression
[43]. A set of such lines was then generated for the first
drug with increasing concentrations of the second drug.
Synergistic inhibition is detected by lines converging at
the left of the y-axis, while parallel lines indicate additiv-
ity. Diverging lines (lines crossing at the right of the y-
axis) indicate antagonism [19].
DEC formation assay
DNA primers D19, D25, and D26 were 5'-end labeled
with T4 polynucleotide kinase (New England Biolabs, Ips-
wich, MA) and [γ-32P]ATP as previously described [69]. All
DNA/DNA primer/templates were annealed by incubat-
ing a 1:1.3 molar ratio of primer to template in 50 mM
Tris-HCl buffer containing 50 mM NaCl at 90°C for 3
min, 50°C for 10 min, and left on ice for 10 min. The
annealed primer/templates were analyzed by non-dena-
turing polyacrylamide gel (4–20% TBE) electrophoresis to
ensure that the proper annealing had taken place.
The ability of HIV-1 RT to form a stable complex with
NRTI-terminated primer/template in the presence of
dNTP, ddNTP or NNRTI was assessed as previously
described with modification [19,50,51]. Two sets of
primer/templates were tested using D19/D36A (D19/
D36C) and D25/D50 (D26/D50). Labeled primer/tem-
plate was chain-terminated by incubating a mixture con-
taining 50 mM Tris-HCl (pH 7.8), 60 mM KCl, 5 mM
MgCl2, 5 mM DTT, 300 μg/mL bovine serum albumin, 4.2
(v/v) % glycerol, 5 nM [5'-32P]-labeled primer/template,
0.5 μM of ddATP or TFV-DP (for D19/D36A or D25/D50)
or 0.5 μM of ddCTP or FTC-TP (for D19/D36C or D26/
D50), and 200 nM HIV-1 RT for 5 min at 37°C and then
placed on ice. A fraction of the reaction mixture was saved
and later analyzed by sequencing gel electrophoresis
(16% polyacrylamide, 8 M urea). All of the primers tested
were shown to be > 95% extended to n+1 product. Free
dNTP, ddNTP, or EFV was added into the mixture and the
mixture was incubated for 15 min at 25°C. At the end of
the incubation, the mixture was placed on ice and mixed
with 100 mM KCl and 1 A260 unit/mL (for D19/D36A and
D19/D36C) or 5 A260 unit/mL (for D25/D50 and D26/
D50) poly(rA).poly(dT)12–18. Control studies showed that
DEC is intact in the presence of high salt 100 mM KCl,
while regular binary RT/primer-template complexes dis-
sociate and RT is trapped by cold poly (rA).poly (dT)12–18
and is prevented from rebinding to 32P-labeled DNA. After
incubation at 37°C for 5 min, the reaction mixture was
cooled on ice, mixed with native loading dye (30% glyc-
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erol, 0.25% bromophenol blue) and analyzed on a 6%
non-denaturing polyacrylamide gel in 0.5 × TBE buffer
(0.45 M Tris-borate, 0.01 M EDTA, pH 8.3) on ice for 1 h
(100 volts). The gel was exposed to a storage phosphor
screen and DEC formation was quantified using GE Storm
820 PhosphorImager and ImageQuant TL software (GE
Healthcare, Piscataway, NJ).
The DEC formation was analyzed by plotting the fraction
of the primer/template detected as a function of dNTP,
ddNTP, or EFV concentration. Examples of dCTP, FTC-TP,
and EFV-facilitated DEC formation and the data fittings
are illustrated in Fig 5. Data were fitted by nonlinear
regression to simple ligand binding equation: y = (Bmax ×
[ligand])/(Kd + [ligand]) using SigmaPlot 9.0 (Systat Soft-
ware, Inc., San Jose, CA), where the ligand is the free
dNTP, ddNTP, or EFV concentration, and y corresponds to
the % of primer/template in DEC complex. The kinetic
constants Kd represents the apparent dissociation constant
of a ligand and Bmax is the maximum % of DEC complex
formation.
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